Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 16/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30615104 | 0.88 | USP1 (0.39) | USP1PTGS2HSD11B1 | |
| SCHEMBL25343216 | 0.88 | USP1 (0.39) | USP1PTGS2HSD11B1 | |
| SCHEMBL22143119 | 0.87 | USP1 (0.45) | USP1PTGS2 | |
| SCHEMBL26627861 | 0.84 | USP1 (0.48) | USP1PTGS2 | |
| SCHEMBL25975294 | 0.81 | NT5E (0.44) | PTGS2HSD11B1 | |
| SCHEMBL22122019 | 0.79 | USP1 (0.50) | USP1 | |
| SCHEMBL25346673 | 0.78 | PTGS2 (0.40) | PTGS2HSD11B1 | |
| SCHEMBL25975478 | 0.78 | EGLN2 (0.38) | PTGS2HSD11B1 | |
| SCHEMBL30615090 | 0.78 | PTGS2 (0.40) | PTGS2HSD11B1 | |
| SCHEMBL29864073 | 0.75 | USP1 (0.37) | USP1PTGS2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4472946-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | Exelixis, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | USP1 1/4885PTGS2 3006/4885HSD11B1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.